Latest News

Germany to pump €1bn into breakthrough innovation

German Research Minister Anja Karliczek and Economics Minister Peter Altmaier make a joint statement on the founding of the Agency for Jump Innovations following the meeting of the Federal Cabinet. © BMBF / Hans-Joachim Rickel


by tg

Germany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be funded with roughly €1bn over 10 years.

The move is intented to keep value creation in Germany.  The idea for such an agency is lent from the US agency DARPA (Defense Advanced Research Projects Agency), which was founded by President Dwight D. Eisenhower in the 1950ies to support commercialisation of groundbreaking inventions such as the Internet, GPS or driverless vehicles. Besides Germany, Sweden and Switzerland have already established innovation agencies for non-military purposes. 

The German agency is set to start next year. According to Germany’s minister for economics, Peter Altmaier, a first call will seek for 3 to 4 promising artificial intelligence projects.

Vaximm goes East for cancer vaccine deal

T-cell immunotherapy expert Vaximm plans to use Artificial Intelligence (AI) to develop personalised cancer vaccines. The biotech is collaboration...

Azeria Therapeutics bags €37.3m in Series B financing round

Series A lead investor CRT Pioneer Fund co-financed the Series B financing round. Azeria said it will use the proceeds to develop its preclinical...

Belgian start-up takes fight on neuropathies

„Augustine was a famous patient of famous French neurologist Jean-Martin Charcot‚” Ward Capoen, Principal at V-Bio Ventures, told...

Magenta Therapeutics exercises ATAC licence option

Stem cell specialist Magenta Therapeutics (Cambridge, MA, USA) agreed to pay up to $85m in milestones for the rights to exclusively develop and...

Novo secures Dicerna’s RNAi liver assets

Under the deal, which includes potential treatments for NASH, orphan liver diseases, obesity and diabetes, Dicerna could theoretically earn...

Urokinase clears blot clots in stroke patients

Endovascular mechanical thrombectomy has been the gold standard procedure for treating stroke patients with an occluded cerebral artery since 2015...

BioVersys receives up to €8m from CARB-X

Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial...